Moonwalk Biosciences

Executive Summary

Moonwalk Biosciences, founded in 2022 and headquartered in Cambridge, MA, is a pre-clinical biotechnology company pioneering a new class of therapeutics in adipose biology by targeting the epigenetic code. The company’s platform integrates human genetics and epigenomics to discover and validate causal targets for metabolic diseases, with an initial focus on obesity. Unlike genetic editing approaches, Moonwalk aims to reprogram cells to a healthy state by modulating epigenetic marks, potentially offering a reversible and tunable therapeutic modality. This approach could address the complex, polygenic nature of obesity and other metabolic disorders by correcting dysregulated gene expression without altering the underlying DNA sequence. Currently operating at the pre-clinical stage, Moonwalk Biosciences is positioned to capitalize on the growing understanding of epigenetics in metabolic health. The company’s deep focus on adipose biology—long overlooked in the obesity drug landscape—differentiates it from GLP-1-based therapies. If successful, Moonwalk’s platform could yield disease-modifying treatments that not only reduce weight but also improve metabolic complications. The company is likely to seek Series A financing to advance its lead programs toward IND-enabling studies, with potential interest from strategic partners in the metabolic space.

Upcoming Catalysts (preview)

• 2026Series A Financing Announcement70% success
• 2027Preclinical Proof-of-Concept Data for Lead Obesity Program50% success
• 2026Research Collaboration or Licensing Deal with a Large Pharma40% success